SNS-595, a naphthyridine cell cycle inhibitor and stimulator of apoptosis for the treatment of cancers

Current Opinion in Investigational Drugs

Volumn 9, Issue 6, 2008, Pages 647-657

  Mills, D A ^a   Fekrazad, H M ^a   Verschraegen, C F ^a  

^a UNIVERSITY OF NEW MEXICO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CAMPTOTHECIN; CARBOPLATIN; CISPLATIN; CYTARABINE; DACTINOMYCIN; DAUNORUBICIN; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; GELDANAMYCIN; GEMCITABINE; IRINOTECAN; METHOTREXATE; MITOMYCIN C; NAPHTHYRIDINE DERIVATIVE; PACLITAXEL; PEMETREXED; SNS 595; TOPOTECAN; WORTMANNIN;

ACUTE LEUKEMIA; ALOPECIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTHRALGIA; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RESISTANCE; CELL CYCLE ARREST; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIARRHEA; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; DYSGEUSIA; FATIGUE; FEBRILE NEUTROPENIA; HEADACHE; HEMATOLOGIC MALIGNANCY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INTESTINE OBSTRUCTION; LEUKOPENIA; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEOPLASM; NEUTROPENIA; NONHUMAN; OVARY CANCER; PATENT; REVIEW; SINGLE DRUG DOSE; SOLID TUMOR; STRUCTURE ACTIVITY RELATION; THROMBOCYTOPENIA; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; HUMANS; NAPHTHYRIDINES; NEOPLASMS; PATENTS AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STRUCTURE-ACTIVITY RELATIONSHIP; THIAZOLES;

EID: 44649121141     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (61)

1. 119586 The anthracyclines: Will we ever find a better doxorubicin? Weiss RB SEMIN ONCOL 1992 19 6 670-686
2. 322014 Antitumor activity of a novel quinolone DNA topoisomerase II inhibitor AG-7352. Nakano K, Kashimoto S, Sato Y, Kajikawa F, Ota S, Abe S, Chiba K PROC AM ASSOC CANCER RES 1999 40 Abs 767
3. 389780 In vivo antitumor activity of a novel quinolone analogue AG-7352 against a broad spectrum of cancers and drug-resistant human cancers. Sato Y, Kashimoto S, Kajikawa F, Ota S, Tomita K, Abe S, Nakano K NCI EORTC SYMP NEW DRUGS CANCER THER 2000 11 254
4. 402250 Antitumor activity of a novel quinolone analog AG-7352 in human xenograft models of leukemia or drug resistant tumors and in an experimental metastic tumor model. Kashimoto S, Sato Y, Kajikawa F, Ota S, Abe S, Okugawa K, Tsuzuki Y, Nakano K PROC AM ASSOC CANCER RES 2001 42 Abs 553
5. 474173 Synthesis and structure-activity relationships of novel 7-substituted 1,4-dihydro-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acids as antitumor agents. Part 1. Tomita K, Tsuzuki Y, Shibamori K, Tashima M, Kajikawa F, Sato Y, Kashimoto S, Chiba K, Hino K J MED CHEM 2002 45 25 5564-5575
6. 509028 Sunesis licenses Dainippon's anticancer compound. Sunesis Pharmaceuticals Inc PRESS RELEASE 2003 October 15
7. 530484 ADMET and pharmacokinetic properties of SPC-595, a novel cell cycle inhibitory antineoplastic agent in non-clinical species. Hoch U, Evanchik MJ, Kondo K, Mizuki Y, Walker DH, Silverman JA PROC AM ASSOC CANCER RES 2004 45 Abs 5394
8. 547834 Synthesis and structure-activity relationships of novel 7-substituted 1,4-dihydro-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acids as antitumor agents. Part 2. Tsuzuki Y, Tomita K, Shibamori K, Sato Y, Kashimoto S, Chiba K J MED CHEM 2004 47 8 2097-2109
9. 584334 Synthesis and structure-activity relationships of 3-substituted 1,4-dihydro-4-oxo-1-(2-thiazolyl)-1,8-naphthyridines as novel antitumor agents. Tsuzuki Y, Tomita K, Sato Y, Kashimoto S, Chiba K BIOORG MED CHEM LETT 2004 14 12 3189-3193
10. 595778 SNS-595, a novel cell cycle inhibitor in phase I clinical trials, causes tumor regressions, cell-cycle arrest, and apoptosis in murine models of colon cancer. Hoch U, Hyde J, Nannini MA, Evanchik MJ, Lawrence CE, Arkin MR, Walker DH, Silverman JA PROC AM ASSOC CANCER RES 2005 46 Abs 2277
11. 595781 The potent cytotoxic agent SNS-595 causes a rapid onset of apoptosis during the S-phase of the cell cycle. Hyde J, Wright J, Silverman JA, Walker DH, Arkin MR PROC AM ASSOC CANCER RES 2005 46 Abs 2285
12. 595787 The phase I clinical compound SNS-595 acts during S-phase and causes a sustained G2 arrest. Hyde J, Wright J, Osheroff N, Silverman JA, Walker DH, Arkin MR PROC AM ASSOC CANCER RES 2005 46 Abs 2293
13. 626607 Dainippon and Sumitomo merge to form Dainippon Sumitomo Pharma Dainippon Sumitomo Pharma Co Ltd PRESS RELEASE 2005 October 03
14. 637261 CYP450 inhibition, induction, metabolism, and routes of elimination of SNS-595, a novel cell cycle inhibitor currently in phase I clinical trials. Hoch U, Evanchik MJ, Silverman JA CLIN CANCER RES 2005 11 23 Suppl Abs C221
15. 640646 SNS-595, a novel S-phase active cytotoxic, demonstrates pharmacologic properties appropriate for the treatment of advanced hematologic malignancies. Lawrence CE, Arbitrario JP, Kumer JL BLOOD 2005 106 11 Abs 4632
16. 659374 SNS-595 causes selective double strand breaks during S-phase which are solely repaired through non-homologous end joining. Hyde J, Wright J, Walker DH, Silverman JA, Arkin MR PROC AM ASSOC CANCER RES 2006 47 Abs 2074
17. 659379 SNS-595 has synergistic activity in vitro with DNA damaging agents and antimetabolites. Wright J, Hyde J, Silverman JA, Walker DH, Arkin MR PROC AM ASSOC CANCER RES 2006 47 Abs 2132
18. 659382 A phase 1 trial of weekly SNS-595 in patients (PTS) with refractory cancer. Ebbinghaus S, Gordon M, Advani R, Hurwitz H, Mendelson D, Wakelee H, Hoch U, Silverman J, Havrilla N, Adelman D PROC AM ASSOC CANCER RES 2006 47 Abs 2913
19. 659383 SNS-595, a novel S-phase active cytotoxic, exhibits potent in vitro and in vivo activities, and has the potential for treating advanced hematologic malignancies. Lawrence CE, Arbitrario JP, Kumer JL, Wright J PROC AM ASSOC CANCER RES 2006 47 Abs 4726
20. 670953 SNS-595 demonstrates clinical activity and dose-proportional pharmacokinetics (PK) in two phase I clinical studies. Hurwitz H PROC AM SOC CLIN ONCOL 2006 25 Abs 3062
21. 683431 Sunesis Pharmaceuticals Reports Second Quarter 2006 Financial Results. Sunesis Pharmaceuticals Inc PRESS RELEASE 2006 August 10
22. 748905 A phase 1 dose-escalation study of the novel cell cycle active agent SNS-595 in advanced leukemias. Lancet JE, Karp JE, Havrilla N, Hoch U, Silverman J, Adelman D, Giles FJ BLOOD 2006 108 11 Abs 1962
23. 750055 SNS-595 a novel S phase active cytotoxic acts synergistically with cytarabine to reduce bone marrow cellularity and circulating neutrophils. Arbitrario J, Kumer J, Howlett A, Silverman J BLOOD 2006 108 11 Abs 2321
24. 761223 Sunesis' SNS-595 shows mixed anticancer efficacy in phase II trials. Sunesis Pharmaceuticals Inc PRESS RELEASE 2007 January 29
25. 778364 Phase I trial of SNS-595 in patients with advanced malignancies. Advani R, Gordon M, Hurwitz H, Mendelson D, Wakelee H, Ebbinghaus S, Hoch U, Silverman J, Havrilla N, Adelman D J CLIN ONCOL 2005 23 16 Suppl 2099
26. 778373 Non-clinical ADMET, PK, and biological activity of SNS-595, a novel cell cycle inhibitory antineoplastic agent. Evanchik MJ, Hoch U, Walker D, Silverman JA DRUG METAB REV 2004 36 Suppl 1 103
27. 778383 Synthesis and antitumor activity of novel 7-substituted 1,4-dihydro-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acids. Tomita K, Tsuzuki Y, Shibamori K, Kashimoto S, Chiba K ACS 1999 217 1-2 MEDI 249
28. 813478 NCT00408603: Safety and efficacy clinical study of SNS-595 in patients with platinum-resistant ovarian cancer. Sunesis Pharmaceuticals Inc CLINICALTRIALS.GOV 2007
29. 818324 Sunesis Pharmaceuticals reports second quarter 2007 financial results. Sunesis Pharmaceuticals Inc PRESS RELEASE 2007 August 02
30. 829606 Sunesis begins phase I and Ib trials of SNS-595 and SNS-314 for cancer. Sunesis Pharmaceuticals Inc PRESS RELEASE 2007 September 12
31. 843110 A phase II trial of SNS-595 in women with platinum resistant epithelial ovarian cancer. McGuire W, Matulonis U, Hirte H, Husain A, Chiang A, Aghajanian C, Hawtin R, Goldberg Z AACR-NCI-EORTC INT CONGRESS 2007 19 Abs A158
32. 845021 SNS-595 potentiates the in vivo antitumor activity of carboplatin, cisplatin, and gemcitabine in solid tumor xenografts. Kumer JL, Arbitrario JP, Jones JJ, Henjarappa N, Hoch U, Silverman JA, Howlett AR, Scatena CD AACR-NCI-EORTC INT CONGRESS 2007 19 Abs 659
33. 846888 NCT00541866: Safety and tolerability study of SNS-595 and cytarabine combination in acute myeloid leukemia in humans. Sunesis Pharmaceuticals CLINICALTRIALS.GOV 2007 October 09
34. 866020 SNS-595 demonstrates clinical responses in a phase I study in acute leukemia. Lancet J, Kantarjian H, Ravandi F, Bastien S, Alino K, Michelson G, Karp J AM SOC HEMATOL ANN MEET EXPOSITION 2007 49 Abs 442
35. 877210 Synthesis and structure-activity relationships of potent antitumor active quinoline and naphthyridine derivatives. Srivastava SK, Jha A, Agarwal SK, Mukherjee R, Burman AC ANTICANCER AGENTS MED CHEM 2007 7 6 685-709
36. 888426 A phase 2 trial of SNS-595 in women with platinum resistant epithelial ovarian cancer. McGuire W, Matulonis U, Hirte H, Hussain A, Penson R, Chiang A, Aghajanian C, Young D, Fox JA, Bolton M, Michelson G SOCIETY GYNECOLOGIC ONCOLOGISTS ANN MEET 2008 Abs 293
37. 888704 SNS-595: Preliminary results of 2 phase 2 second line studies in lung cancer. Burris H, Krug L, Shapiro G, Fidias P, Crawford J, Reiman T, Michelson G, Young D, Adelman D, Ettinger D EUR J CANCER 2007 5 4 Abs 6547
38. 888886 NCT00607997: Study of SNS-595 in older patients with untreated acute myeloid leukemia. Sunesis Pharmaceuticals Inc CLINICALTRIALS.GOV 2008 February 08
39. 889044 Results of a phase 1 clinical trial of SNS-595 in patients with advanced solid malignancies. Advani R, Gordon M, Hurwitz H, Mendelson D, Wakelee H, Ebbinghaus S, Hoch U, Silverman J, Havrilla N, Adelman D AACR-NCI-EORTC INT CONGRESS 2007 17 November 16
40. 889057 An extension study of IV SNS-595 in patients responsive to SNS-595 in previous studies (SPO-0003): An open-label, multicenter, extension study of intravenously administered SNS-595 in patients responsive to SNS-595 in previous cancer clinical studies. Premiere Oncology, A Medical Corporation INTERNET SITE 2008 March 25
41. 889058 A study of SNS-595 in patients responsive to SNS-595 in previous studies (SPO-0008): An open-label, multicenter, extension study of intravenously administered SNS-595 in patients responsive to SNS-595 in previous cancer clinical trials. Premiere Oncology, A Medical Corporation INTERNET SITE 2008 March 25
42. 889498 Sunesis Pharmaceuticals: Pipeline & products. Sunesis Pharmaceuticals Inc COMPANY WORLD WIDE WEB SITE 2008 March 26
43. 889499 NCT00408603: Safety and efficacy clinical study of SNS-595 in patients with platinum-resistant ovarian cancer. Sunesis Pharmaceuticals Inc CLINICALTRIALS.GOV 2008 March 20
44. 889502 Synthesis and antitumor properties of bis(quinaldine) derivatives. Sinha BK, Philen RM, Sato R, Cysyk RL J MED CHEM 1977 20 11 1528-1531
45. 889504 Synthesis and cytotoxic activity of carboxamide derivatives of benzo[b][1,6]naphthyridines. Deady LW, Rodemann T, Zhuang L, Baguley BC, Denny WA J MED CHEM 2003 46 6 1049-1054
46. 889505 Synthesis and antitumor activity of some new substituted quinolin-4-one and 1,7-naphthyridin-4-one analogs. el-Subbagh HI, Abadi AH, al-Khawad IE, al-Rashood KA ARCH PHARM 1999 332 1 19-24
47. 889506 Benzo[b]-1,8-naphthyridine derivatives: Synthesis and reversal activity on multidrug resistance. Misbahi H, Brouant P, Hevér A, Molnár AM, Wolfard K, Spengler G, Mefetah H, Molnár J, Barbe J ANTICANCER RES 2002 22 4 2097-2101
48. 894088 Sensitivity to SNS-595 is related to activation of double strand repair pathways including homologous recombination. Hawtin RE, Stockett D, Kimmel RA, Evensen E, Wong OK, Taverna P, Fox JA AM ASSOC CANCER RES ANN MEET 2008 99 Abs 1859
49. 894089 SNS-595 is a potent anti-tumor agent that has a dual mechanism of action: DNA intercalation and site-selective topoisomerase II poisoning. Stockett D, Byl JA, Hawtin RE, Tan N, Zhu Y, Arkin MR, Yang W, McDowel RS, Osheroff N, Fox JA AM ASSOC CANCER RES ANN MEET 2008 99 Abs 1860
50. 895852 Ex vivo activity of SNS-595 against biopsies of acute myeloid leukemia, triple negative breast and ovarian cancers supports ongoing and potential clinical indications. Hawtin RE, Mamuszka H, Arkin MR, Fox JA AM ASSOC CANCER RES ANN MEET 2008 99 Abs 2830
51. 897819 EP-00787726: Novel compound, process for producing the same, and antitumor agent. Tomita K, Chiba K, Kashimoto S, Shibamori K-I, Tsuzuki Y EUROPEAN PATENT 2001 November 28
52. 899722 SNS-595 cancer therapeutic: Novel DNA damage agent. Sunesis Pharmaceuticals Inc COMPANY PRESENTATION 2008 March 13
53. 899727 DNA topoisomerases: Structure, function, and mechanism. Champoux JJ ANNU REV BIOCHEM ANNU REV BIOCHEM 2001 70 369-413
54. 900302 Neutropenia: State of the knowledge part I. Nirenberg A, Bush AP, Davis A, Friese CR, Gillespie TW, Rice RD ONCOL NURS FORUM 2003 33 6 1193-1201
55. 900313 Risks and consequences of chemotherapy-induced neutropenia. Lyman GH CLIN CORNERSTONE 2006 8 Suppl 5 S12-S18
56. 900339 Ovarian cancer symptoms, symptoms of ovarian cancer, ovarian cancer prognosis and more: Ovarian cancer prognosis. OvarianCancerPrognosis. net INTERNET SITE 2008 April 28
57. 900340 Chemotherapy for ovarian cancer. Cancer Research UK INTERNET SITE 2008 April 28
58. 901692 Etopophos (etoposide phosphate) for injection. Bristol-Myers Squibb Co DRUG PACKAGE INSERT 2005 March 31
59. 901717 MedlinePlus drug information: Etoposide phosphate. National Institutes of Health, National Library of Medicine INTERNET SITE 2008 April 17
60. 901745 Drugs and supplements: Doxorubicin (intravenous route). Mayo Foundation for Medical Education and Research INTERNET SITE 2007 December 01
61. 901746 Drugs and supplements: Doxorubicin hydrochloride liposome (intravenous route). Mayo Foundation for Medical Education and Research INTERNET SITE 2007 December 01